A Laure et Bérénice, qui m'ont accompagnée durant ce semestre à tour de rôle ,
A New Anti-oestrogenic Agent in Late Breast Cancer ,
Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels, BMJ, vol.1, issue.5844, pp.13-17, 1973. ,
DOI : 10.1136/bmj.1.5844.13
Adjuvant therapy of the very young woman. The Breast, pp.16-136, 2007. ,
Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?, European Journal of Cancer, vol.35, issue.12, pp.1625-1632, 1999. ,
DOI : 10.1016/S0959-8049(99)00204-X
Health-Related Quality of Life and Tamoxifen in Breast Cancer Prevention: A Report From the National Surgical Adjuvant Breast and Bowel Project P-1 Study, Journal of Clinical Oncology, vol.17, issue.9, pp.2659-69, 1999. ,
DOI : 10.1200/JCO.1999.17.9.2659
The Royal Marsden Hospital pilot tamoxifen chemoprevention trial, Breast Cancer Res Treat, vol.31, issue.1, pp.73-82, 1994. ,
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial, The Lancet, vol.352, issue.9122, pp.98-101, 1998. ,
DOI : 10.1016/S0140-6736(98)85012-5
TAMOXIFEN AND CONTRALATERAL BREAST CANCER, The Lancet, vol.326, issue.8449, p.282, 1985. ,
DOI : 10.1016/S0140-6736(85)90338-1
Comparison between tamoxifen and clomiphene therapy in women with anovulation, Archives of Gynecology, vol.6, issue.4, pp.297-88, 1979. ,
DOI : 10.1111/j.1471-0528.1973.tb11230.x
EFFECT OF THE ANTI-OESTROGEN TAMOXIFEN ON PLASMA LEVELS OF LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE, PROLACTIN, OESTRADIOL AND PROGESTERONE IN NORMAL PRE-MENOPAUSAL WOMEN, Journal of Endocrinology, vol.70, issue.3, pp.421-429, 1976. ,
DOI : 10.1677/joe.0.0700421
Current overview of EORTC clinical trials with tamoxifen, Cancer Treat Report, vol.60, pp.1463-1469, 1976. ,
Clinical inducers of ovulation : comparative results, Int J Fertil, vol.24, pp.61-65, 1979. ,
A COMPARISON OF THE EFFECTS OF CLOMIPHENE AND TAMOXIFEN TREATMENT ON THE CONCENTRATIONS OF OESTRADIOL AND PROGESTERONE IN THE PERIPHERAL PLASMA OF INFERTILE WOMEN, Clinical Endocrinology, vol.80, issue.5, pp.381-390, 1978. ,
DOI : 10.1111/j.1471-0528.1973.tb11230.x
Treatment of Fibrocystic Mastopathy by an Antiestrogen, Tamoxifen, International Journal of Gynecology & Obstetrics, vol.89, issue.5, pp.348-50, 1980. ,
DOI : 10.1136/bmj.1.5844.13
Alteration of Endocrine Parameters in Premenopausal Women With Breast Cancer During Long-Term Adjuvant Therapy With Tamoxifen as the Single Agent, JNCI Journal of the National Cancer Institute, vol.83, issue.20, pp.1488-91, 1991. ,
DOI : 10.1093/jnci/83.20.1488
Endocrine status of premenopausal node positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen ,
Effets secondaires médicaux d'une intervention de chimioprévention : l'exemple du tamoxifène, Bull Cancer, vol.82, issue.3, pp.186-206, 1995. ,
Endocrine Consequences of Continuous Antiestrogen Therapy with Tamoxifen in Premenopausal Women, Journal of Clinical Investigation, vol.64, issue.2, pp.398-404, 1979. ,
DOI : 10.1172/JCI109475
Endocrine effets of adjuvant chemotherapy and longterm tamoxifen administration on node-positive patients with breast cancer, Cancer Res, vol.47, pp.624-654, 1987. ,
Ovarian torsion in a premenopausal woman treated with tamoxifen for breast cancer**Supported in part by grant HD24563 from the National Institutes of Health, Bethesda, Maryland., Fertility and Sterility, vol.59, issue.2, pp.459-60, 1993. ,
DOI : 10.1016/S0015-0282(16)55688-X
Ovarian Overstimulation and Cystic Formation in Premenopausal Tamoxifen Exposure: Comparison between Tamoxifen-Treated and Nontreated Breast Cancer Patients, Gynecologic Oncology, vol.72, issue.2, pp.202-209, 1999. ,
DOI : 10.1006/gyno.1998.5201
Successful co-treatment with LH-RH-agonist for ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure, Breast Cancer Res Treat, vol.55, issue.2, pp.119-141, 1999. ,
Ovarian cysts in tamoxifen-treated premenopausal women with breast cancer???A management dilemma, American Journal of Obstetrics and Gynecology, vol.172, issue.4, pp.1323-1327, 1995. ,
DOI : 10.1016/0002-9378(95)91511-7
Gynaecological effects of tamoxifen, Journal of Clinical Pathology, vol.52, issue.2, pp.83-91, 1999. ,
DOI : 10.1136/jcp.52.2.83
Paraovarian cystic endosalpingiosis in association with tamoxifen therapy, Journal of Clinical Pathology, vol.53, issue.2, pp.161-163, 2000. ,
DOI : 10.1136/jcp.53.2.161
Ovarian cysts in women receiving tamoxifen for breast cancer, British Journal of Cancer, vol.132, issue.11-12, pp.11-121761, 1999. ,
DOI : 10.1093/oxfordjournals.aje.a116427
URL : http://www.nature.com/bjc/journal/v79/n11/pdf/6690280a.pdf
Torsion of a Functional Ovarian Cyst in a Premenopausal Patient Receiving Tamoxifen, Gynecologic and Obstetric Investigation, vol.48, issue.3, pp.200-202, 1999. ,
DOI : 10.1159/000010174
Evaluation of tamoxifen dose in advanced breast cancer : a progress report, Cancer Treat Rep, vol.60, issue.10, pp.1451-1460, 1976. ,
Comparison of endometrial changes among symptomatic tamoxifen-treated and non treated premenopausal and postmenopausal breast cancer patients ,
Tamoxifen and menopausal status: risks and benefits, The Lancet, vol.347, issue.9003, p.761, 1996. ,
DOI : 10.1016/S0140-6736(96)90111-7
Risk of endometrial cancer in premenopausal women on tamoxifen, The Lancet, vol.352, issue.9138, p.1476, 1998. ,
DOI : 10.1016/S0140-6736(05)61308-6
Place des inhibiteurs de l???aromatase dans le cancer du sein de la femme m??nopaus??e, en situation adjuvante: les acquis et les incertitudes en 2005, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.35, issue.4, pp.327-367, 2006. ,
DOI : 10.1016/S0368-2315(06)76405-5
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer., Journal of Clinical Oncology, vol.14, issue.5, pp.1718-1747, 1996. ,
DOI : 10.1200/JCO.1996.14.5.1718
Tamoxifen and Ovarian Function, PLoS ONE, vol.8, issue.2, p.66616, 2013. ,
DOI : 10.1371/journal.pone.0066616.t003
URL : https://doi.org/10.1371/journal.pone.0066616
National Cancer Institute of Canada Clinical Trials Group. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study ,
Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer, Journal of Clinical Oncology, vol.24, issue.36, pp.5769-79, 2006. ,
DOI : 10.1200/JCO.2006.07.2793
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?, The Lancet, vol.355, issue.9218, pp.1869-74, 2000. ,
DOI : 10.1016/S0140-6736(00)02292-3
Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons, Clinical Breast Cancer, vol.7, issue.2, pp.158-61, 2006. ,
DOI : 10.3816/CBC.2006.n.026
Determinants of self rated menopause status, Maturitas, vol.27, issue.3, pp.223-232, 1997. ,
DOI : 10.1016/S0378-5122(97)00043-1
A pragmatic approach to the classification of menopausal status for community-based research, Menopause, vol.15, issue.5, pp.978-83, 2008. ,
DOI : 10.1097/gme.0b013e318162c487
Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates, Maturitas, vol.67, issue.1, pp.60-66, 2010. ,
DOI : 10.1016/j.maturitas.2010.04.015
Cystic ovarian necrosis complicating tamoxifen therapy for breast cancer in a premenopausal woman. A case report, J Reprod Med, vol.35, issue.3, pp.299-300, 1990. ,
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trial, European Journal of Cancer, vol.28, issue.2-3, pp.2-3673, 1992. ,
DOI : 10.1016/S0959-8049(05)80123-6
URL : https://hal.archives-ouvertes.fr/hal-00616696
Ovarian Tumors in Postmenopausal Breast Cancer Patients Treated with Tamoxifen, Gynecologic Oncology, vol.60, issue.1 ,
DOI : 10.1006/gyno.1996.0011
Therapeutic approach to ovarian cysts in tamoxifen-treated women with breast cancer, International Journal of Gynecology & Obstetrics, vol.125, issue.3, pp.249-53, 1996. ,
DOI : 10.1210/endo-125-3-1739
Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer, American Journal of Obstetrics and Gynecology, vol.174, issue.1, pp.141-145, 1996. ,
DOI : 10.1016/S0002-9378(96)70386-1
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, JNCI: Journal of the National Cancer Institute, vol.97, issue.22, pp.1652-62, 2005. ,
DOI : 10.1016/j.ejca.2004.10.020
Clinical and biomarker predictors of side effects from tamoxifen, Breast Cancer Research and Treatment, vol.14, issue.2, pp.1107-1125, 2012. ,
DOI : 10.1097/01.gme.0000233496.13088.24
Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites, BMC Cancer, vol.70, issue.4, p.612, 2013. ,
DOI : 10.1016/j.maturitas.2011.09.011
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes, Clinical Pharmacology & Therapeutics, vol.169, issue.5, pp.718-743, 2011. ,
DOI : 10.1093/aje/kwp077
URL : http://europepmc.org/articles/pmc3081375?pdf=render
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients, J Natl Cancer Inst, vol.104, issue.6, pp.452-60, 2012. ,
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer : the breast international groupe 1-98 trial, J Natl Cancer Inst, vol.104, issue.6, pp.441-51, 2012. ,
Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters, Journal of Clinical Oncology, vol.31, issue.2, pp.176-80, 2012. ,
DOI : 10.1200/JCO.2012.44.6625
Tamoxifen, hot flashes and recurrence in breast cancer, Breast Cancer Research and Treatment, vol.22, issue.3, pp.421-427, 2008. ,
DOI : 10.1093/jnci/djg108
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial, The Lancet Oncology, vol.9, issue.12, pp.1143-1151, 2008. ,
DOI : 10.1016/S1470-2045(08)70259-6
Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism, Cancer, vol.18, issue.19, pp.4442-4451, 2009. ,
DOI : 10.1002/cncr.24508
Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer., Journal of Clinical Oncology, vol.9, issue.2, pp.286-94, 1991. ,
DOI : 10.1200/JCO.1991.9.2.286
Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis, Journal of Clinical Oncology, vol.17, issue.1, pp.120-129, 1999. ,
DOI : 10.1200/JCO.1999.17.1.120